AI주식인사이트AI Stock Insight
B

제일약품

271980KOSPI의약품 제조업

62.7 / 100

Reference Date: 2026-07-24

Financial Score26.5 / 40
News Sentiment17.2 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but Revenue is on a declining trend. Slightly up 2.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Jeil Pharm was established in 2017 through a spin-off from Jeil Pharma Holdings, focusing on the manufacturing and sales of finished pharmaceutical products. Its subsidiary, Oncol Therapeutics, specializes in new drug development. Key products include treatments for hypercholesterolemia, hyperlipidemia, and gastric cancer, with major revenue contributors being Lipito tablets and Lyrica capsules.

Number of Employees

1,011people

Average Salary

63.8M KRW

Score Calculation Basis

Detailed Financial Score

PER
4.53Industry Average 11.238.0Point

Half of industry avg (excellent)

PBR
0.58Industry Average 0.815.5Point

Lower than industry avg (good)

ROE
13.61Industry Average 4.017.0Point

3.4x industry avg (excellent)

Debt Ratio
6.81Industry Average 12.435.0Point

Lower than industry avg (good)

Trend 2023~20251.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼11.3% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼53.7% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 0.3% (improving, 3yr)

Detailed News Sentiment

9 totalPositive 5Neutral 3Negative 1Average Sentiment Score 68.9

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 9,860Won52-week high 17,39052-week low 9,550
1-month return3.0Point

1m 1.96% (flat)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0